ZEISS Medical Technology has announced that the National Medical Products Administration (NMPA) in China has approved the VISUMAX 800 with SMILE pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
The latest generation of femtosecond lasers from ZEISS enters the China market at a time when more than 10 million eyes have been treated with ZEISS SMILE and SMILE pro worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia, Europe and the US.
The VISUMAX 800 with SMILE pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz. Additionally, the shorter procedure time can reduce stress for surgeons and their patients. The ZEISS femtosecond laser also provides greater flexibility for the surgeon and patient, with a smaller footprint and compatibility with a variety of patient beds, adapting to the clinical environment to provide cutting-edge technology without compromise.
With the availability of the VISUMAX 800 with SMILE pro software from ZEISS in China, surgeons can utilise a number of workflow enhancements including: the CentraLign centration aid, a computer-controlled function for easy centration; the OcuLign cyclotorsion adjustment to help counter cyclotorsion that may occur; and VISULYZE user nomograms to help surgeons collect and analyze patient data, while also providing detailed nomograms and enabling more control during every surgery.
With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX 800 with SMILE pro software from ZEISS offers substantial market opportunities for surgeons in China.
